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Abstract
Primary familial brain calcification (PFBC) is a neurological disease characterized by calcium 
phosphate deposits in the basal ganglia and other brain regions, thus far associated with SLC20A2, 
PDGFB, or PDGFRB mutations. We identified in multiple PFBC families mutations in XPR1, a 
gene encoding a retroviral receptor with phosphate export function. These mutations alter 
phosphate export, providing a direct evidence of an impact of XPR1 and phosphate homeostasis in 
PFBC.
PFBC, also known as idiopathic basal ganglia calcification, or Fahr’s disease, is a rare, 
clinically heterogeneous neurodegenerative disorder1. PFBC symptoms typically occur after 
the age of 40, with progressive neuropsychiatric and movement disorders, although some 
individuals may remain asymptomatic. Clinical features include dystonia, parkinsonism, 
ataxia, psychosis, dementia, chorea, and frontal-subcortical cognitive dysfunction. Bilateral 
calcifications of the basal ganglia are visualized on computed tomography (CT) scans. 
PFBC is genetically heterogeneous, typically inherited in an autosomal-dominant fashion. 
Causative mutations have been found in SLC20A22,3, which encodes the phosphate 
transporter PiT24, in PDGFRB5, which encodes the platelet-derived growth factor receptor 
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β, and in PDGFB6, which encodes the PDGFRβ main ligand. Altogether, the three genes 
account for 49% of PFBC families in our cohort3.
We evaluated a North American family of Swedish ancestry with PFBC7, lacking mutations 
in SLC20A2, PDGFB, and PDGFRB. Our analysis included 17 members (9 affected, 3 
unaffected, and 5 individuals of unknown status, Supplementary Figure 1a). When assessed, 
the clinical presentation consisted of dementia, speech impairment (slurred speech, 
palilalia), chorea, and unsteady gait (Supplementary Table 1)8. CT brain scans showed 
extensive intracranial calcifications in basal ganglia extending to cerebral cortex or 
cerebellum.
Exome sequencing was performed in 4 affected (III-4, III-5, III-9, IV-6) and 1 unaffected 
(II-5) family members. A total of 83,848 variants were identified in the 5 samples 
(Supplementary Figure 1b). We first filtered out variants present in dbSNP 138 and present 
with a frequency >1% in the 1000 Genomes Project and Exome Variant Server databases. 
We then focused on missense, splice site, stop-gain/loss and frameshift variants. Seven 
variants (Supplementary Table 2) segregated with the disease in these five samples and were 
then assessed in all 17 available family members using Sanger sequencing. Only one variant 
was present in all affected individuals while absent in unaffected members (maximum LOD 
score 3.6): a c.434T>C (NM_004736.3) transition in the mammalian xenotropic and 
polytropic retrovirus receptor 1 (XPR1) gene, predicted to induce a deleterious p.Leu145Pro 
change of a highly-conserved residue within the SPX domain shared by SYG1/PHO81/
XPR1 proteins9 (Fig. 1a), and absent from repositories of sequence variation, including the 
Exome Aggregation Consortium (ExAC) database.
Further XPR1 sequencing in 86 additional sporadic and familial cases exposed the same 
p.Leu145Pro variant in two affected individuals from a family of French descent, and five 
additional missense variants. Pedigree analyses and segregation of variants surrounding 
XPR1 suggested that the two families carrying p.Leu145Pro were not related 
(Supplementary Material). Three other variants, p.Ser136Asn, p.Leu140Pro and 
p.Leu218Ser (Table 1, Fig. 1a, Supplementary Figure 2, and Supplementary Table 3), all 
located in the SPX domain or in its vicinity and predicted to be damaging, were absent from 
variation repositories. The p.Lys53Arg variant, also absent from variation databases, is 
predicted to be non-damaging. The p.Ile575Val variant has a 0.068% minor allele frequency 
in ExAC, interchanges two hydrophobic residues in a transmembrane domain and is likely 
to represent a rare polymorphism. None of these variants were found in two in-house series: 
126 French and 161 North-American Caucasian controls were screened with exome 
sequencing or targeted resequencing, respectively.
XPR1 is a cell-surface multipass membrane protein initially identified as the mammalian 
receptor for xenotropic-murine leukemia viruses (X-MLV)9,10. It contains an amino-
terminal SPX domain (Fig. 1a) that is also found in several yeast and plant proteins involved 
in phosphate homeostasis11,12. We have recently shown that XPR1 mediates phosphate 
export13, a function highly conserved across evolution13,14. We tested all the XPR1 novel 
variants in a complementation assay for phosphate efflux in human cells13, wherein 
phosphate efflux decrease after introduction of XPR1-targeting siRNA (siXPR1) is followed 
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by efflux restoration upon introduction of wild type or mutated XPR1 (Fig. 1b). We found 
that p.Leu145Pro-mutated XPR1 neither re-established phosphate efflux, nor served as 
receptor for X-MLV infection (Fig. 1b and Supplementary Table 4). Consistent with this 
observation, phosphate efflux was also impaired in PBMC of the two patients harboring the 
p.Leu145Pro mutation whom we tested (Fig. 1e). This mutation affected cell surface 
exposure of XPR1 on HEK293T cells as monitored by flow cytometry with a XPR1 ligand 
(XRBD) derived from the X-MLV envelope glycoprotein13, although the p.Leu145Pro 
XPR1 expression remained substantial (Fig. 1c-d). Remarkably, expression of p.Leu145Pro 
XPR1 specifically decreased phosphate efflux of endogenous XPR1 (Fig. 1b) while no 
effect on expression of phosphate importers PiT1 and PiT2 and phosphate uptake was 
observed (Supplementary Figure 3), supporting a trans-dominant negative effect of the 
p.Leu145Pro mutation on wild-type XPR1. In contrast, the four other variants were present 
at the plasma membrane and served as potent retroviral receptors (Supplementary Figure 4 
and Supplementary Table 4). The three variants, p.Ser136Asn, p.Leu140Pro, and 
p.Leu218Ser, all affected XPR1 activity at various degrees, despite normal expression of the 
three phosphate transporters PiT1, PiT2 and XPR1 (Supplementary Figure 4). Expression of 
XPR1 with the predicted non-damaging p.Lys53Arg substitution restored phosphate efflux 
to wild-type levels, making the causative role of this variant in PFBC uncertain.
With SLC20A22,3, XPR1 is thus the second PFBC-associated gene to encode a phosphate 
transporter. PFBC-causing mutations in SLC20A22,3 (PiT2) suggest that inhibition of 
phosphate uptake may lead to deposition of calcium phosphate in the vascular extracellular 
matrix. In contrast, inhibition of phosphate export, associated with the XPR1 mutations, is 
expected to increase intracellular phosphate concentration. Therefore, XPR1 mutation-
mediated calcium phosphate precipitation is likely to occur intracellularly, as is 
characteristic of osteoblasts during bone mineralization15.
Phosphate import and export are interdependent functions that regulate intracellular 
phosphate homeostasis. However, it is not yet known whether XPR1 and PiT2 co-regulate 
each other and/or are regulated by common factors. The PFBC-associated PDGFRB and 
PDGFB proteins, also known to modulate phosphate transport, may also function as 
regulators of XPR1 and PiT2 levels in the brain5,6,16. PiT1 and PiT2 expression is 
modulated by extracellular phosphate concentration17 and we have recently reported that 
high phosphate medium increases phosphate export while starvation decreases it13. It is 
therefore possible that alterations of PiT2-mediated phosphate transport may also alter 
XPR1-dependent phosphate export in areas of the brain where phosphate transporters are 
expressed18.
Five out of six XPR1 variants described in this study are clustered in the cytoplasmic N-
terminal part of XPR1 (Fig. 1a), and four lie in the SPX domain, which appears dispensable 
for intrinsic phosphate export activity13. A role of SPX in protein trafficking may explain 
the retention of the p.Leu145Pro XPR1 variant in cells. Interestingly, this mutation disrupts 
a di-leucine motif known to be involved in protein endocytosis and plasma membrane 
trafficking19, and highly conserved across evolution (Supplementary Figure 5). The other 
mutants with impaired phosphate efflux activity were efficiently addressed to the plasma 
membrane, suggesting function(s) other than trafficking for the SPX domain. Thus, the SPX 
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domain was shown to modulate intracellular cAMP levels presumably through interactions 
with G protein β subunits20, although its role in phosphate regulation remains to be 
elucidated.
XPR1 is actively expressed in neuronal stem cells13, human brain10, and in several mouse 
brain regions (Allen Mouse Brain Atlas database, http://mouse.brain-map.org). Direct 
involvement of XPR1 in phosphate export and its expression pattern in brain support its role 
in cerebral phosphate homeostasis. These results identify XPR1 as a novel gene associated 




Patient enrollment—Seventeen individuals from one family were enrolled in this study 
through the UCLA Medical Center after providing informed consent. The clinical features of 
this family were described in a previous report7. Additional 86 cases self-defined as 
Caucasian with a clinical diagnosis of idiopathic brain calcification (either sporadic or with 
family history of brain calcifications) and with no mutations in SLC20A2, PDGFB, and 
PDGFRB, were recruited at collaborating institutions. Some of these individuals were 
included in previous clinical or genetic studies (47 of them were recruited using inclusion 
criteria as previously described21). The study was approved by the UCLA Institutional 
Review Board. Patients gave informed, written consent for genetic analyses. Medical history 
and neurological examinations were performed in all probands and additional family 
members. Serum calcium and parathormone levels were assayed to exclude calcium 
dysregulation and other metabolic disorders that would cause brain calcifications unrelated 
to PFBC.
Neuroimaging—Head computed tomography (CT scans) were performed as part of the 
diagnostic workup or reviewed for the presence of calcifications or other brain 
abnormalities. Subjects with CT scans positive for calcifications were given an affected 
disease status, while CT-negative patients >50 years who remained asymptomatic until their 
death were assigned an unaffected disease status. Subjects whose CT scans were negative 
but were under the age of 50, or whose CT scan results were not available, were classified as 
unknown.
Exome analysis
Genomic DNA was extracted from peripheral blood and fragmented by sonication using the 
Covaris acoustic disruptor (E210, Covaris Inc.) to achieve an average fragment size of 200 
base pairs. One microgram of DNA from each individual was used for the construction of a 
paired-end library, exome capture was performed using the TruSeq DNA Sample Prep Kit 
(Illumina).
Sequencing was performed on an Illumina Genome Analyzer HiSeq2500 following the 
manufacturer’s instructions. 46.4 million 100-base, paired-end reads were obtained per 
sample on average, with a 20x average depth of coverage within the targeted exome. Raw 
Legati et al. Page 5
Nat Genet. Author manuscript; available in PMC 2015 December 01.
image files were processed with the Illumina CASAVA 1.8 software (Illumina). The 
sequencing reads were aligned to the National Center for Biotechnology Information human 
reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA). Variant 
calling was performed using Genome Analysis Toolkit (GATK, version 2.6.4) and 
QIAGEN’s Ingenuity Variant Analysis™ software (QIAGEN) was used for variants 
annotation and filtering. Filtration was carried out applying a series of steps (Supplementary 
Figure 1b): low-quality variants were filtered out using the Illumina Qscore threshold of 20; 
in addition, variants present in dbSNP138 and with a minor allele frequency (MAF) higher 
than 1% in the 1000 Genomes Project data (http://www.1000genomes.org/) and Exome 
Variant Server (EVS, http://evs.gs.washington.edu/EVS/) databases were filtered out; 
finally, we focused on predicted missense, frameshift, stop gain/loss, and splice-site 
variants. The potential effect of the variants on the protein function was assessed by 
Polyphen2, SIFT and Mutation Taster. Polyphen2 is a software tool that predicts damaging 
effects combining an evaluation of the properties of the mutated amino acid and of the 
conservation of the residue22. SIFT is a tool developed to predict the deleterious effect of an 
amino acid substitution basing on sequence homology analysis23. Mutation Taster is a web-
based application that integrates information from several analysis tools. The disease 
potential is evaluated comprising analysis on evolutionary conservation, splice-site changes, 
loss of protein features and changes that might affect the amount of mRNA24. Residue 
conservation was evaluated using the Genomic Evolutionary Rate Profiling (GERP), an 
algorithm that identifies constrained elements in multiple alignments by quantifying 
substitution deficits25. GERP score ranges from –12.3 to 6.17, with 6.17 being the most 
conserved elements. Protein schematic (Fig. 1a) was created using TOPO2, Transmembrane 
protein display software (http://www.sacs.ucsf.edu/TOPO2). Variant frequency was also 
checked in Exome Aggregation Consortium (ExAC), database, Cambridge, MA (URL: 
http://exac.broadinstitute.org) [accessed February 2015], where XPR1 has a mean coverage 
= 65.2x (range: 41–206x) across 115,519.9 alleles on average.
Sanger Sequencing analysis
Sanger sequencing was initially performed to screen the genes already known to be 
associated with PFBC (i.e. SLC20A2, PDGFRB, PDGFB) and to validate the variants 
identified through exome sequencing. Genomic DNA extracted from the blood was used as 
template for PCR reactions in order to amplify the coding regions of SLC20A2 
(NM_001257180.1), PDGFB (NM_002608.2) and PDGFRB (NM_002609.3), as well as 
that of XPR1 (NM_004736.3), focus of this study.
Cosegregation analysis
The maximum LOD score (recombination rate = 0) was computed assuming an autosomal 
dominant pattern of inheritance, a penetrance of 100% at age 50 (12 informative meioses 
fulfilling these criteria), according to the formula Z ( θ) = log [(1 – θ)n–r θr/(1/2)n], where n = 
total number of births, r = number of recombinant types, and θ = recombination rate.
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Analysis of relatedness between the two families carrying the c.434T>C, p.Leu145Pro 
XPR1 variant
We studied the genealogy of both families whose members included carriers of the c.
434T>C, p.Leu145Pro variant. We obtained data up to the 1750s in one branch of the 
French family (mother of the proband, known to be affected) and could not find any 
common ancestry with the North-American family of Swedish descent. Furthermore, we 
compared exome sequencing from all affected and unaffected individuals from the North-
American family in XPR1 and the surrounding genes on chromosome 1, and identified three 
variants (one downstream and two upstream of XPR1) that were present in affected and 
absent in the unaffected individual: rs7536561 (529 kb from the XPR1 variant), rs79485039 
(113 kb from the XPR1 variant), and rs3747958 (125 kb from the XPR1 variant). We 
sequenced these SNPs in the proband of the French family who also carried the c.434T>C, 
p.Leu145Pro mutation and found reference sequences for all of them. This supported the 
hypothesis that the mutation occurred on different haplotypes in the two families.
Cells
HEK293T (human embryonic kidney) and CHO hamster cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS, Invitrogen) and non-essential amino 
acids, in a 5% CO2 incubator at 37°C under humid atmosphere. For phosphate-free 
incubations, cells were grown in phosphate-free DMEM supplemented with 10% dialysed 
FBS.
Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood collected 
in presence of heparin from both healthy donors and patients who have signed informed 
consent for research purposes. Blood samples were subjected to density gradient separation 
on Histopaque-1077 (ratio 1:1) (Sigma-Aldrich) and centrifuged 24 hours after blood 
collection. After centrifugation, the PBMC layer was collected and washed in DMEM 
before evaluation of phosphate efflux.
Plasmids and siRNAs
The p.Leu145Pro, p.Lys53Arg, p.Ser136Asn, p.Leu140Pro and p.Leu218Ser mutations were 
generated by site-directed mutagenesis using recombinant PCR (details are available upon 
request). The HA-tagged versions of human XPR1 were introduced in both the pCHIX 
expression vector26 and pLXSN retroviral vector27. Sequences of small interfering RNAs 
(siRNA, Integrated DNA Technologies) targeting the 3’ UTR of human XPR1 were as 
follows: 5’-ggauuucaugccaucccautt-3’ and 5’-gcacuuccaccauguauuatt-3’. siRNA directed 
against the firefly luciferase gene was used as control. HEK293T cells grown on poly-D-
lysine coated 6-well plates were transfected with 50 pmol siRNA per well using the calcium 
phosphate method.
33Phosphate fluxes in human cells
Phosphate uptake and efflux from HEK293T cell monolayers transfected 2 days prior to 
assays were measured as previously described9. Briefly, for uptake measurements, cells 
were incubated 30 min at 37°C in phosphate-free DMEM supplemented with 0.5µCi/ml 
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[33P]phosphate (NEZ080500UC, Perkin Elmer). Cell lysates were then assayed for 
radioactivity by scintillation counting and for protein content by the BCA protein assay 
(Pierce). The percentage of phosphate uptake was calculated as the ratio of cellular 
[33P]phosphate to total [33P]phosphate supplemented. For the efflux measurements, cells 
were incubated 20 min at 37°C in phosphate-free DMEM supplemented with 0.5µCi/ml 
[33P]phosphate (NEZ080500UC, Perkin Elmer), gently washed three times with phosphate-
free medium and then incubated in DMEM for 30 min at 37°C in 10mM phosphate before 
collecting the supernatant. [33P]phosphate in the supernatants and cell lysates was measured 
by liquid scintillation. The percentage of phosphate efflux was calculated as the ratio of 
released [33P]phosphate to total cellular [33P]phosphate. Phosphate efflux in PBMC was 
assayed as described above with 0.5×106 cells per assay.
Immunoblotting
Whole cell extracts (15µg) were analyzed on 12% SDS-PAGE under reducing conditions, 
transferred to PVDF membranes and probed with antibodies against HA (3F10, 1:5000, 
Roche Applied Science) or β-actin (A5441, 1:5000, Sigma-Aldrich). Proteins of interest 
were detected with horseradish peroxidase-conjugated anti-mouse or anti rat antibodies 
(1:5000, SouthernBiotech) and visualized with the Pierce ECL Western blotting substrate 
(Thermo Scientific), according to the manufacturer’s protocol.
Flow Cytometry
Cell surface expression of phosphate transporters was monitored on HEK293T cells with 
soluble ligands derived from the receptor-binding domain (RBD) of different Env. 
Xenotropic-MLV RBD (XRBD), koala retrovirus (KoRV) RBD (KoRBD) and 
amphotropic-MLV RBD (ARBD) were used to detect XPR1, PiT1 and PiT213,28, 
respectively. Binding assays were carried out as previously described13. Briefly, 5×105 cells 
were resuspended in 200µl PBA (PBS with 2% FBS and 0.1% sodium azide) containing the 
proper RBD, incubated for 30 min at 37°C, washed twice with PBA and incubated for 20 
min at 4°C with Alexa488-conjugated anti-mouse IgG1 antibodies (1/500 dilution, 
Invitrogen). Cells were immediately analyzed on a FACSCalibur (Becton Dickinson) and 
data analysis was performed using FlowJo software.
Virus production
LAPSN virus vectors were produced in 2×106 HEK293T cells in 10 cm dishes cotransfected 
using calcium phosphate with the MLV-based LAPSN retroviral vector carrying the alkaline 
phosphatase reporter gene29 (10µg), the MLV Gag/Pol expression vector (pC57GPBEB, 
5µg)30, and either the vesicular stomatitis virus (VSV) G protein or the X-MLV envelope 
glycoprotein (Env) expression vectors (5µg). Virion-containing media were harvested 2 days 
later, filtered through 0.45 µm (pore size) filter and stored at -80°C before use. LXSN virus 
vectors carrying wild type and mutated XPR1 genes were produced in the same conditions 
except that the LAPSN retroviral vector was replaced by the various XPR1 LXSN vectors.
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Viral Infection and G418 selection
CHO cells stably expressing XPR1 constructs were generated by transducing CHO cells 
with the pL(XPR1)SN, pL(XPR1K53R)SN, pL(XPR1S136N)SN, pL(XPR1L140P)SN, 
pL(XPR1L145P)SN, pL(XPR1L218S)SN or empty pLXSN vectors and selected the next 
day with medium containing 1.5 mg per ml of G418 (active fraction). G418-resistant clones 
were pooled after 2 weeks of selection before further experiments.
2×104 hamster CHO cells, stably expressing wild type, p.Lys53Arg, p.Ser136Asn, 
p.Leu140Pro, p.Leu145Pro or p.Leu218Ser XPR1 from the MLV-based retroviral vector 
LXSN, were plated in 12-well plates and infected the following day with serial dilutions of 
replication-defective LAPSN retroviral vector pseudotyped with X-MLV Env or the VSV-G 
glycoprotein. Cells were stained 2 days later for alkaline phosphatase (AP) expression, as 
previously described29, and AP-positive colonies were counted to determine viral titers 
(colony forming units per ml).
Statistical analysis
The Student’s t test in GraphPad Prism 5 software (GraphPad) was used to calculate P 
values, and the following convention was used: *P≤0.05; ** P≤0.01; *** P≤0.001; **** 
P≤0.0001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Localization of the Variants Identified in the XPR1 Protein and Effect of the 
p.Leu145Pro on Protein Expression and Function
(a) Schematic representation of the XPR1 protein and the variants identified in this study. 
The SPX domain is in orange. (b) Efflux of inorganic 33P in HEK293T cells transfected 
with siLUC (Lane 1), siXPR1 alone (Lane 2) or in combination with HA-tagged wild type 
(Lane 3) or p.Leu145Pro XPR1 (Lane 4). Results are means ± s.e.m. in a representative 
experiment (n=3); **P≤0.01 and ***P≤0.001 as tested against siLUC. (c) Immunoblot of 
HA-tagged XPR1 expression in cell lysates with an anti-HA antibody (upper panel). β-actin 
was used as loading control (lower panel). (d) Cell-surface detection of XPR1 on HEK293T 
cells transfected as in (b). Nonspecific staining with the secondary IgG antibody (filled 
histograms) and specific binding with X-MLV RBD (solid line histograms) are represented. 
Numbers indicate specific mean fluorescence intensity of a representative experiment (n=3). 
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(e) Efflux of 33P in PBMC collected from two control healthy donors (each symbolized by 
circles or squares), and two affected patients harboring the p.Leu145Pro mutation (each 
symbolized by triangles pointing up or down). Bars represent means ± s.e.m., ***P ≤ 0.001.
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